Elevated nuclear factor erythroid-2 levels promote Epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients

Stem Cells Translational Medicine

Volumn 2, Issue 2, 2013, Pages 112-117

  Bogeska, Ruzhica ^a,b   Pahl, Heike L ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adult hematopoietic stem cells; Hematopoietic progenitors; Myeloproliferative disorders; Transcription factors

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 6; MESSENGER RNA; SHORT HAIRPIN RNA; STEM CELL FACTOR; THROMBOPOIETIN; TRANSCRIPTION FACTOR NF E2;

ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; ERYTHROCYTOSIS; ERYTHROID CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERSENSITIVITY; LENTIVIRUS INFECTION; MYELOID PROGENITOR CELL; POLYCYTHEMIA VERA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STEM CELL EXPANSION;

EID: 84876511310     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0046     Document Type: Article

References (25)

1. Lasho TL, Mesa R, Gilliland DG et al. Mutation studies in CD3, CD19 and CD34 cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005;130:797-799.
2. Jamieson CH, Gotlib J, Durocher JA et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006;103:6224-6229.
3. Anand S, Stedham F, Beer P et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011;118: 177-181.
4. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
5. Lacout C, Pisani DF, Tulliez M et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108: 1652-1660.
6. Kralovics R, Teo SS, Li S et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006;108:1377-1380.
7. Cario H, Goerttler PS, Steimle C et al. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005;130:800-801.
8. Jones AV, Chase A, Silver RT et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446-449.
9. Goerttler PS, Kreutz C, Donauer J et al. Gene expression profiling in polycythaemia vera: Overexpression of transcription factor NF-E2. Br J Haematol 2005;129:138-150.
10. Wang W, Schwemmers S, Hexner EO et al. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood 2010;116:254-266.
11. Kaufmann K, Gründer A, Hadlich T et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med 2012; 209:35-50.
12. Mutschler M, Magin AS, Buerge M et al. NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol 2009;146:203-217.
13. Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IRAC Press, 2008.
14. Steimle C, Lehmann U, Temerinac S et al. Biomarker analysis in polycythemia vera under interferon-alpha treatment: Clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 2007;86: 239-244.
15. Weber K, Bartsch U, Stocking C et al. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008;16:698-706.
16. Roelz R, Pilz IH, Mutschler M et al. Of mice and men: Human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol 2010;38:792-797.
17. Ugo V, Marzac C, Teyssandier I et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-187.
18. Garçon L, Lacout C, Svinartchouk F et al. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. Blood 2005;105:1448-1455.
19. Sokol L, Luhovy M, Guan Y et al. Primary familial polycythemia: A frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995;86:15-22.
20. Kralovics R, Indrak K, Stopka T et al. Two new EPO receptor mutations: Truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997;90:2057-2061.
21. Kralovics R, Sokol L, Prchal JT. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Invest 1998;102:124-129.
22. Perrotta S, Cucciolla V, Ferraro M et al. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One 2010;5:e12015.
23. Ang SO, Chen H, Hirota K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-621.
24. Randrianarison-Huetz V, Laurent B, Bardet V et al. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythromegakaryocytic progenitor stage. Blood 2010; 115:2784-2795.
25. Doulatov S, Notta F, Eppert K et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 2010;11:585-593.